In addition, we evaluated the CUSP06 efficacy in CDH6-positive uterine cancer and cholangiocarcinoma PDX models, where the therapeutic potential of CDH6-targeted ADCs has not previously been demonstrated. This evidence concerns the gene CDH6 and cholangiocarcinoma.